3. Wu YL, et al. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell...
英文标题:A phase I/II study of davutamig (REGN5093), a MET×MET bispecific antibody, in patients with MET-altered, advanced non-small cell lung cancer (aNSCLC): Trial in progress update 中文标题:一项在MET改变的...
2024年世界肺癌大会（WCLC）于9月7日至10日在美国圣地亚哥盛大举行。在此次会议上，广东省人民医院的杨衿记教授团队公布了其关于“Osimertinib with or without Savolitinib as 1L in denovo MET aberrant, EGFRm advanced NSCLC (CTONG 2008, FLOWERS): A Phase Ⅱ trial”的研究成果。该研究，也被称为FLOWERS研...
Herein, we describe a signal-seeking study evaluating ABBV-400 treatment in patients with select solid tumors.Methods:Multicenter, open-label, phase 1 signal-seeking study(NCT06084481). Eligible patients (≥18 years) have confirmed locally advanced/metastatic disease measurable per RECIST v1.1 and ...
伯瑞替尼此次被纳入《2024 CSCO指南》,获得Ⅳ期MET 14外显子跳跃突变NSCLC一线治疗及后线治疗Ⅰ级推荐,是鞍石生物科技在产品研发、临床研究的长期积累和结晶,也是MET 14外显子跳跃突变NSCLC治疗的新里程碑,将使得更多MET 14外显子跳跃突变NSCLC患者获益于精准靶向治疗!
7. Dagogo-Jack I, Moonsamy P, Gainor JF, et al. A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. J Thorac Oncol 2021;16:850-9. 8. Jamme P, Fernandes M, Copin MC, et al. Alterations in the PI3K Pathway Drive Resistanc...
图1.杨衿记教授WCLC现场报告FLOWERS研究(CTONG2008) 摘要号:PL04.10 英文标题:Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial 中文标题:奥希替尼联合或不联合赛沃替尼一线治疗原发MET异常合并EGFR突变晚期NSCLC(CTONG 2008):一项...
A phase IIIb study of savolitinib in patients with locally advanced or metastatic NSCLC harboring MET exon 14 mutation 汇报人:张永昌教授(中南大学湘雅医院) 类别:口头报告(Mini Oral session 1) 摘要编号:1MO 日期及时间:2024年3月20日,16:30 - 17:30 ...
MET Exam Dates 2025 - MAHE has announced the MET 2025 exam date on the official website, manipal.edu. Check important dates, registration, admit card and result dates at Careers360.com.
当地时间3月20日下午,湖南省肿瘤医院张永昌教授于大会现场进行了题为“赛沃替尼治疗MET 14外显子跳跃突变局部晚期或转移性非小细胞肺癌(NSCLC)的 IIIb 期研究[A Phase 3b Study of Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation]”的简短口头报告。现将研究...